عرض بسيط للتسجيلة

المؤلفAchkar I.W.
المؤلفAbdulrahman N.
المؤلفAl-Sulaiti H.
المؤلفJoseph J.M.
المؤلفUddin S.
المؤلفMraiche F.
تاريخ الإتاحة2019-10-17T07:44:38Z
تاريخ النشر2018
اسم المنشورJournal of Translational Medicine
المصدرScopus
الرقم المعياري الدولي للكتاب14795876
معرّف المصادر الموحدhttp://dx.doi.org/10.1186/s12967-018-1471-1
معرّف المصادر الموحدhttp://hdl.handle.net/10576/12158
الملخصCisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin. - 2018 The Author(s).
اللغةen
الناشرBioMed Central Ltd.
الموضوعApoptosis
Cisplatin
Combination therapy
Mitogen activated protein kinase
P90 ribosomal s6 kinase
Synergy
العنوانCisplatin based therapy: The role of the mitogen activated protein kinase signaling pathway
النوعArticle Review
رقم العدد1
رقم المجلد16
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة